Listen

Description

For people who have lost the ability to speak, brain-computer interfaces (BCIs) could open a new path back to communication. In this episode, Adam Fraser speaks with Matt Angle, founder and CEO of Paradromics, about the company’s 11-year journey to build a BCI that can restore communication for people who have lost it. Matt explains why moving more neural data is central to BCI performance and how Paradromics is approaching safety, durability and clinical translation. He breaks down why speech restoration is the company’s first clinical focus, then unpacks what could come next, including movement applications, mood biomarkers and AI-enabled communication. The conversation also explores the company’s move from Silicon Valley to Austin, Texas, as well as the regulatory, reimbursement, funding and commercial realities of building in deep tech, and what it takes to turn frontier neuroscience into a durable company. Listen in for a closer look at Paradromics’ journey and the technology, capital and strategic thinking shaping the future of BCI.

Key Points From This Episode:

Links Mentioned in Today’s Episode:

Derrick Matthew Buchanan on LinkedIn

Canada Neuro

Royal World Archive

Derrick Buchanan, Ph.D. Clinical Neuroscience 

‘The complex landscape of TMS devices: A brief overview’

‘A visual and narrative timeline of US FDA milestones for Transcranial Magnetic Stimulation (TMS) devices’

‘Should rTMS be considered a first-line treatment for major depressive episodes in adults?’

‘Stanford neuromodulation therapy for treatment-resistant depression: a randomized controlled trial confirming efficacy, and an EEG study providing insight into mechanism of action and a potentially predictive biomarker of efficacy’

‘Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression’

Matt Angle on LinkedIn

Paradromics

Paradromics | Connexus

Matt Angle on Substack

‘CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices’

Adam Fraser on LinkedIn

Omniscient Neurotechnology

The Business of Neurotech Podcast